Clinical Trial Update: Dextromethorphan as an Augmentation Agent in Treatment-resistant Schizophrenia [Phase 4]

View source ↗

Summary

This update notes the completion of a Phase 4 clinical trial evaluating dextromethorphan as an augmentation therapy for treatment-resistant schizophrenia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Dextromethorphan (dextromethorphan)

Snippet

Sponsor: All India Institute of Medical Sciences, Bhubaneswar | Conditions: Treatment Resistant Schizophrenia | Phase 4 | Status: COMPLETED